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Summary
Objective: The objective of this study was to characterize the rat monosodium iodoacetate (MIA)-induced model for osteoarthritis (OA) and
determine the translatability of this model to human disease. This was accomplished through pathway, network and system level comparisons
of transcriptional proﬁles generated from animal and human disease cartilage.
Methods: An OA phenotype was induced in rat femorotibial joints following a single injection of 200 mg MIA per knee joint for a period of 2 or 4
weeks. Lesion formation in the rat joints was conﬁrmed by histology. Gene expression changes were measured using the Agilent rat whole ge-
nome microarrays. Cartilage was harvested from human knees and gene expression changes were measured using the Agilent human arrays.
Results: One thousand nine hundred and forty-three oligos were differentially expressed in the MIA model, of these, approximately two-thirds
were up-regulated. In contrast, of the 2130 differentially expressed oligos in human disease tissue, approximately two-thirds were down-
regulated. This dramatic difference was observed throughout each level of the comparison. The total overlap of genes modulated in the
same direction between rat and human was less than 4%. Matrix degradation and inﬂammatory genes were differentially regulated to
a much greater extent in MIA than human disease tissue.
Conclusion: This study demonstrated, through multiple levels of analysis, that little transcriptional similarity exists between rat MIA and human
OA derived cartilage. As disease modulatory activities for potential therapeutic agents often do not translate from animal models to human
disease, this and like studies may provide a basis for understanding the discrepancies.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is a common degenerative disease that
occurs when steady-state homeostasis of the main struc-
tural cartilage macromolecules, aggrecan and type II colla-
gen, is altered, disturbing the ﬁne balance between
anabolism and catabolism of the extracellular matrix
(ECM). Most individuals over the age of 70 have some ev-
idence of symptomatic or radiographic OA1. Many animal
models have been developed as tools to study the mecha-
nisms of OA and to evaluate new drug candidates. There-
fore, the identiﬁcation of molecular pathways that drive the
OA phenotype in these animal models becomes critical to
predict efﬁcacy of potential drug candidates and translat-
ability to human disease. As most animal models are rapid
in progression, it is likely that most, or all, studied to date
have some limitations in their usefulness as tools for the
study of human OA.
Multiple species have been utilized for the study of OA
including rats2, guinea pigs3, dogs4 and rabbits5. The in vivo
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according to the method of OA induction. One approach
is the use of animals that develop genetic or spontaneous
OA and another approach relies on a physical insult (surgi-
cal or chemical) to establish the OA phenotype6,7. It should
be noted that many caveats exist in utilizing any of the
aforementioned models to approximate human OA due to
inherited variation, such as biomechanical differences be-
tween two legged and four legged species.
One of the models used is the monosodium iodoacetate
(MIA) model where rat knees are subjected to intra-articular
injections of MIA. The MIA inhibits glyceraldehyde-3-phos-
phate dehydrogenase activity resulting in chondrocyte
death and lesion formation8. Histological changes in sub-
chondral bone and articular cartilage in this model have
been described9. In addition, several other groups have
used this model to study pain associated with OA and
tested potential analgesic agents10e13.
Transcriptional proﬁling of cartilage offers one signiﬁcant
advantage compared to other tissue types in that chondro-
cytes are the sole cell type found in cartilage. Thus any tran-
scriptional dis-regulation in OA cartilage is due to deviation
of chondrocytes from homeostasis. Several groups have
employed microarray technology to understand regulation
of gene expression in arthritis14,15. For example, Aigner
et al. compared the anabolic and catabolic gene expression
patterns in osteoarthritic and normal cartilage16. In this90
1191Osteoarthritis and Cartilage Vol. 15, No. 10study, we have characterized the molecular proﬁle of chon-
drocytes from the rat MIA model using the rat whole genome
arrays. This proﬁle was then compared to that of human OA
chondrocytes at multiple levels. This study differs from most
previous work that focused on gene expression changes in
cell lines. To date, very few studies have reported genome
wide expression changes for animal models and, to the
best of our knowledge, this is the ﬁrst report to compare
an OA animal model directly to human disease.
Materials and methods
INDUCTION OF OA
The procedures used in this study were in accordance with
the guidelines of the Pﬁzer Animal Care and Use Committee.
Male Wistar rats (125e150 g; Charles River, Wilmington,
MA) were housed in solid bottom cages with paper bedding.
Animals were fed US5 rodent chow (Research Diets, New
Brunswick, NJ) with water available ad libitum. For induction
of arthritis, rats were anesthetized with isoﬂurane (Abbott
Laboratories, North Chicago, IL) and given a single intra-
articular injection of 200 mg monosodium iodoacetate (MIA)
(Sigma, St. Louis, MO; cat # I2512) or sterile saline (Baxter,
Deerﬁeld, IL; cat # 68100-026) through the infrapatellar liga-
ment of both knees. MIA was dissolved in sterile saline and
administered in a volume of 30 ml using a 27-gauge 0.5-
inch needle. A Hamilton PB 600-1 repeating dispenser
with a 700 series luer tip microliter syringe (model 750;
Hamilton Company, Reno, NV) was used for precise injec-
tion. Both knees were injected with MIA in order to obtain
sufﬁcient cartilage since disease joints yield a very small
sample. We conﬁrmed that the location and severity of
cartilage lesions looked essentially the same from rats
with one knee injected vs both knees at both 2 and 4
weeks time points.
RAT TISSUE HARVESTING
At 2 and 4 weeks post-MIA or saline injection, 15 rats per
group were euthanized with CO2 overdose. The knee joints
were then dissected to expose the articular cartilage. The
cartilage was carefully dissected away from the subchon-
dral bone using a dissecting microscope. Cartilage from
the tibial plateau, medial and lateral, was harvested, pooled,
and snap frozen in liquid nitrogen. A group of 15 uninjected
normal rats were euthanized, synovial lavage performed,
and the tibial cartilage removed as described above.
HISTOLOGY
At 4weekspost-injection, salineandMIA injected ratswere
euthanizedwith CO2 overdose, the knee joints dissected and
placed in 10% buffered formalin. Samples were sent to
Bolder BioPATH Inc. for processing. Brieﬂy, the joints were
decalciﬁed in 5% formic acid. The knees were trimmed into
two approximately equal frontal halves, processed through
graded alcohols and a clearing agent, inﬁltrated and embed-
ded in parafﬁn, sectioned, and stained with toluidine blue.
Knees were submitted for microscopic evaluation by a board
certiﬁed veterinary pathologist (Dr Alison Bendele).
HUMAN TISSUE PREPARATION
Normal and degenerative adult human femoral and tibial
cartilage were procured from both males and females withinstitutional approval and patient consent. Each joint was
graded using a modiﬁed Collins scale17. Full-thickness artic-
ular cartilage was dissected from load-bearing regions of the
femoral condyle and tibial plateau. Lesion (Collins score>1)
was dissected away from adjacent normal cartilage (Collins
score 0e1). However, the underlying tissue, which is pheno-
typically different from the surface lesion and is not apoptotic/
necrotic in nature, was also retained. Care was taken to
prevent contamination with surrounding joint connective tis-
sues. Upon dissection, all samples were rinsed with Hank’s
Balanced Salt Solution and snap frozen in liquid nitrogen.
The Collins scores in the ﬁnal sample set ranged from 1 to
4 with an approximate distribution of 12%, 35%, 18%, and
35%, respectively.
RNA ISOLATION AND AMPLIFICATION
Prior to RNA isolation, the snap frozen cartilage samples
were pooled. The 2-week MIA set was divided into three
pools consisting of ﬁve animals per pool. The 4-week MIA
set was subdivided into two sets of ﬁve animals per pool,
one set of four animals and one set of three animals. Saline
controls consisted of three pools of ﬁve animals per pool for
each post-surgical time point. The uninjected normal con-
trols consisted of three pools of ﬁve animals per pool.
Each cartilage pool was powdered using a SPEX 6750
freezer mill and 6753 microvials. Total RNA was then pre-
pared from each pool using a modiﬁed TRIzol (Invitrogen)
isolation protocol incorporating additional puriﬁcation steps.
RNA integrity was assessed with an Agilent HP2100 Bio-
analyzer. For human samples, typically 0.2e1.0 g of carti-
lage was snap frozen in liquid nitrogen. Frozen cartilage
was powdered as described above, except 6751 grinding
vials were substituted. The human control consisted of
a pool of nine non-OA individuals. The human OA samples
were prepared individually for comparison to the control
pool.
Ten nanograms of total RNA from each pool was ampliﬁed
for two rounds using a modiﬁed ampliﬁcation protocol (Mes-
sageAmp II aRNA Ampliﬁcation Kit, cat # 1751, Ambion).
The resulting unmodiﬁed aRNA products were assessed
for overall size and quality using an Agilent HP2100 Bioana-
lyzer. Samples were also quantiﬁed using UV spectroscopy
measuring the absorbance at 260 and 280 nm.
REVERSE TRANSCRIPTION POLYMERASE
CHAIN REACTION (RT-PCR)
Secondary validation of 22 differentially expressed rat
genes was done using a Sybr green-based approach.
Random-primed cDNA was generated from 100 ng template
using aTaqmanReverseTranscription kit andprotocol (Cat #
N808-0234, Applied Biosystems). Taqman primers were de-
signed to account for the 30 bias of two round ampliﬁcation
products.Weﬁrstmapped the referencedoligomer sequence
of each selected gene represented on the ratmicroarray to its
corresponding Genbank accession gene sequence. From
the 30 region of each gene, forward and reverse Sybr green
primers were designed using Primer 3 software. If possible,
the predicted amplicon sequence overlapped the microarray
oligomer sequence. This was not always feasible since the 30
untranslated regions of many genes are not always ame-
nable for this approach. Primers were designed for 22 differ-
entially expressed rat genes, including: cathepsinC, collagen
type18,matrixmetalloproteinase (MMP) 3,MMP12,MMP13,
MMP14, GP39, D site of albumin promoter (albumin D-box)
binding protein, dermatopontin, IGF2, WIF1, kruppel like
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1 (BRCA1).
Reactions were set up using a Biomek 2000 robot (Beck-
man Coulter) in a 384-well plate format using Sybr Green
PCR Master Mix (cat # 4309155, Applied Biosystems).
Each gene was assayed in triplicate, using 2.3 ml of diluted
cDNA/well in a total reaction volume of 5 ml. RT-PCR was
done using ABI 7900 Prism Taqman machines. Following
each RT-PCR run, a primer dissociation curve was gener-
ated for each primer set.
MICROARRAY ANALYSIS
Probes were generated from the cartilage total aRNA
samples and labeled post-ampliﬁcation using either Cy3
or Cy5 ﬂuorescent dyes. A total of seven RNA sets (three
2-week MIA and four 4-week MIA) were generated. Agilent
rat whole genome microarrays (41,012 oligomers repre-
senting 19,817 refseq; 18,838 unique genes) were used
for competitive hybridization of the MIA treated samples
and untreated normal controls. Each sample was labeled
twice, once with Cy3/Cy5 and once Cy5/Cy3 for a ﬂuoro-
reverse design. The chips were then scanned using the
Agilent DNA Microarray Scanner. Images were analyzed
using Imagene 5.6 software. Background subtraction was
performed and normalization was completed using the
LOWESS method. After quality control (QC) assessments
at the spot, chip and experiment levels, the fold increase
or decrease of mRNA expression compared to normal tis-
sue was calculated. The fold value reported for each oligo
was the average of the two ﬂips. The oligos where the
values did not ﬂip in the ﬂuoro-reverse were excluded
from the analysis. In addition, a frequency value was calcu-
lated for each oligo (out of seven RNA sets). A cutoff value
of at least 1.7-fold change in at least three out of seven
samples was used to generate a gene list which was then
used for further analysis. Agilent Human 1A (V2 G4110B)
and 1B (G4111A) microarrays (39,746 oligos representing
24,438 unique refseq; 16,412 genes) were used for obtain-
ing the gene expression data from the human samples. A cut-
off value of 1.7-fold in at least 6 out of 17 samples was used.
ANNOTATION AND PATHWAY MAPPING
Annotation for each oligomer was obtained from its best
refseq match (Blast score: 100% identity over entire oligo
length). The differentially expressed genes were classiﬁed
into functional categories based on the GeneOntology. A to-
tal of 1943 preﬁltered set of genes with at least 1.7-fold dif-
ferential expression in three out of seven samples were
used for network generation and pathway analysis. One
thousand and sixty-eight of these were mapped to 1043
rat refseqs and were imported into the Ingenuity Pathway
analysis application (Ingenuity Systems, www.ingenuity.
com). Networks of the overlapping focus genes were then
algorithmically generated based on their connectivity and
ranked based upon a score. This score is based on a
P-value calculation, which calculates the likelihood that
the focus genes that are part of a network are found therein
by random chance alone.
The Ingenuity Pathways Tool was used to generate
a graphical representation of the pathways of interest.
Genes or gene products are represented as nodes, and
the biological relationship between two nodes is repre-
sented as an edge (line). To compare a pathway/network
between two expression studies namely rat and human,the pathway of interest was displayed in one species and
the expression values from the other species were overlaid
onto that using the Ingenuity Pathway Analysis Tool.
ORTHOLOG MAPPING
To compare the rat and human cartilage data, a reference
set mapping the rat oligomers to the human oligomers was
constructed. The NCBI refseq sequences were downloaded
in Feb 2006. The process was as follows.
1. Human refseq transcripts (29,964) compared with the
rat refseq transcripts (24,127) using BLAST18.
2. Reciprocal best hits stored (15,684).
3. Human and rat oligomers were mapped to this refer-
ence set if the oligo matched with a 100% identity
over its entire length (60 bases). Approximately half
of the oligomers on the human chip can be mapped
to a rat oligo.
A match was counted when a rat refseq and its human
ortholog from the above mentioned reference map trended
in the same direction in the respective proﬁling data sets.
The overlap was calculated as the ratio of the number of
‘‘matches’’ to the total differentials with corresponding
orthologs.
Results
HISTOLOGY
Figure 1(A) shows saline injected knee with normal mor-
phology of medial and lateral aspect of joint cartilage. Syno-
vium, cruciates, epiphyseal bone and marrow are normal.
Figure 1(B) is representative of the injury caused by MIA in-
jection at 4 weeks and has been reproduced in multiple stud-
ies. MIA (200 mg) injected intra-articularly induced near total
cartilage loss from the load-bearing regions of both medial
and lateral tibial plateaus, while the lateral femoral condyle
and medial femoral cartilage were relatively unaffected. Cru-
ciates show degeneration and proteoglycan deposition and
synovium shows minimal subacute inﬂammation. Osteo-
phytes are present on both medial and lateral tibial plateaus.
EXPRESSION PROFILE AND GENE CLASSES
An expression proﬁle of differentially regulated transcripts
(oligos) was generated for animals at two time points of 2
and 4 weeks post-injection. A transcript must demonstrate
a 1.7-fold minimum change as compared to uninjected con-
trols in at least three of the seven sample sets. The resulting
data set included 1943 differentially expressed transcripts
meeting these criteria. Of these 1218, representing approx-
imately two-thirds of the total, were up-regulated. This is in
stark contrast to the expression proﬁle in human OA where
nearly two-thirds of the transcripts were down-regulated as
is illustrated in Fig. 2(A). These 1943 transcripts were then
mapped to 1040 refseq sequences and classiﬁed based on
the GO annotations (http://www.geneontology.org) into mo-
lecular functions and biological processes. Details for these
classiﬁcations are available in the Supplemental material.
The comparison between the 2- and 4-week treatment
groups demonstrates the consistency of the model. Nearly
88% of the transcripts were modulated in a similar fashion
at both time points. Approximately 11% were unique to
the 4-week time point while the same was true for only
1% at the 2-week interval.
1193Osteoarthritis and Cartilage Vol. 15, No. 10Fig. 1. Histological evaluation of the rat knee joint. (A) Saline injected knee. Normal morphology of medial (M) and lateral (L) aspect of joint
cartilage is seen. Synovium (S), cruciates (C) and epiphyseal (E) bone and marrow are normal. Arrows delineate medial and lateral tibial tide-
mark. (B) MIA (200 mg) injected knee at 4 weeks. Lateral (L) femoral condyle and medial (M) femoral cartilage were relatively unaffected. Near
total cartilage loss in the load-bearing regions of both medial and lateral tibial plateaus (arrows) is seen. Cruciates (C) show degeneration and
proteoglycan deposition and synovium (S) shows minimal subacute inﬂammation. Osteophytes are present on both medial and lateral tibial
plateaus (red arrows).722
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Fig. 2. (A) Global trends in gene expression. Number of refseqs up-
regulated and down-regulated in MIA and human data sets. About
two-third refseqs are up-regulated in MIA in contrast to two-third
being down-regulated in the human data set. (B) Overlap between
human and MIA proﬁles. Overlap calculated before ﬁltering low end
differentials and after ﬁltering low end differentials, with two
frequency cutoffs gave similar results.SECONDARY VALIDATION
To insure the accuracy of the expression changes, as
predicted by the microarray platform, a total of 238 second-
ary validation data points were generated using RT-PCR.
RT-PCR conﬁrmed the array changes with a validation
rate of 98.3%. Differential regulation was considered to be
conﬁrmed when RT-PCR data agreed with the transcrip-
tional proﬁling results regarding direction of change and
signiﬁcance using a 1.7-fold cutoff point for each sample.
Genes selected for secondary validation fell into four basic
categories: (1) all seven pools up-regulated; (2) all seven
pools down-regulated; (3) a mix of up-regulated and no
disregulated pools; and (4) a mix of down-regulated and
no disregulated pools. No differentially regulated genes
comprising a mixture of up- and down-regulated samples
were identiﬁed in the rat TxP data set.
COMPARISON BETWEEN HUMAN AND RAT PROFILES
To better understand the similarities and differences be-
tween the human and rat tissues, the transcriptional proﬁles
were compared at multiple levels. To insure an accurate
comparison, orthologs were mapped between the species
as described in the Materials and methods section. The
proﬁles were then compared at three levels of granularity,
global, network/pathway, and individual genes/gene
classes.
GLOBAL COMPARISON
The global comparison of MIA to human OA in Fig. 2(A)
typiﬁes the degree of difference observed at each level of
the assessment. In the MIA model, approximately two-thirds
of the observed transcripts are up-regulated while the con-
verse is true in the human OA tissue. Additionally, as illus-
trated in Fig. 2(B), less than 4% of the genes disregulated in
the MIA model trend in the same direction as human OA.
Alternatively, this implies that for 96% of the rat transcripts
differentially expressed in the MIA model, either the human
ortholog was not differentially expressed or was differen-
tially expressed in the opposite direction. To further insure
1194 R. A. Barve et al.: Transcriptional proﬁling and pathway analysis of MIA-induced experimental OA in ratsthat this was not an artifact of sensitivity, only cases where
the rat and human orthologs were detectably expressed on
the arrays were considered in the comparison. Also illus-
trated in Fig. 2(B), is the fact that the percent overlap re-
mained virtually constant regardless of the differential
expression frequency cutoff used for the human transcripts.
An initial frequency cutoff nearest to one-third of the sam-
ples from rat and human was selected for the comparison
to insure that gene changes were not speciﬁc to an individ-
ual. To verify that the results were not a simple artifact of the
chosen cutoff, multiple frequencies were tested. In each
case, the percent overlap was effectively the same, and,
as such, those data are not reported here.
NETWORK/PATHWAY ANALYSIS
The Ingenuity Pathway Analysis Tool was used to com-
pare individual networks between the two tissue sets for all
genes in the overlapping data sets described in the global
comparison. The top scoring networks from MIA are dis-
played in Table I. The network associated with connective
tissue disorders was among the largest networks identiﬁed
and was selected for further comparison. Figure 3 illustrates
this network with the differential expression data from MIA,
included in the coloration of the nodes. Red signiﬁes up-
regulation while green symbolizes down-regulation. Figure 4
represents the same network utilizing expression data fromhuman OA. It is immediately clear that little overlap exists for
this network. Few transcripts trend in the same direction,
while more, including C1QA, CCL2, SerpineA1, CD1D,
and CDKN1A, are opposite. All other networks investigated,
demonstrated the same lack of correlation.
GENE CLASS ANALYSIS: PROTEASES
Increased protease activity is widely accepted as a major
factor in the progression of human OA. MMP3, MMP13 and
aggrecanases (a disintegrin and metalloproteinase with
thrombospondin motifs-4 (ADAMTS-4) and ADAMTS-5)
are examples of proteases that have been reported by
numerous labs to be more active in the human disease
state19e22. Thus, a speciﬁc focus was placed on analysis
of protease regulation. Numerous proteases were signiﬁ-
cantly up-regulated in the MIA treated cartilage as com-
pared to vehicle control. These include MMP2, MMP9,
MMP12, MMP13, MMP14, and MMP23), caspases 1 and
6, cathepsins C, E, K, Y and S and proprotein convertases
(Pcsk1, Pcsk2, and Pcsk5). Table II lists details for the pro-
teases with the mean fold change and frequency (number
of replicates showing the change). Human protease tran-
scriptional dis-regulation pales by comparison with respect
to both number of proteases, and magnitude of change,
as can be seen in Table II. Again, this result was typical
of other gene classes studied in detail.Table I
Top scoring networks in rat cartilage generated using Ingenuity Pathway Analysis Tools. Networks of the 535 focus genes are algorithmically
generated based on their connectivity and ranked based upon a score. The score is based on a P-value calculation, which calculates the
likelihood that the focus genes that are part of a network are found therein by random chance alone. The network highlighted in bold is
associated with connective tissue disorders and was used for further pathway analysis
id Genes Score Focus
genes
Top functions
1 ADARB1, ALCAM, APOE, ARG1, CEBPE, CLEC2D, COL4A1,
CRYAB, DSTN, ECM1, EGLN1, FBXO2, GBP2, HAS2, HUMMLC2B,
LIMK1, LUM, MGST3, MYC, MYOCD, PAM, PCSK1, RELN, RPL7,
S100A6, SLC11A1, SLC25A5, SNRPN, TMSB4X, TPM1, TYMS,
UGT1A1, UGT1A6, UNR, VLDLR
43 35 Cell cycle, free radical scavenging,
cell morphology
2 BUB1B, C1QA, CCL2, CCL6, CCL7, CD74, CD1D, CDH13, CDKN1A,
CTSK, CTSS, CUBN, DPP4, GFI1, HLA-DQB1, HLA-DRA, HLA-DRB1,
KIAA0101, LGALS3, LGALS3BP, MMP2, MMP3, MMP13, MMP14,
NID, PHGDH, PLK2, PRKCH, PRTN3, RACGAP1, S100A4,
SERPINA1, TCN2, TFPI2, TIMP1
43 35 Post-translational modiﬁcation,
connective tissue disorders,
inﬂammatory disease
3 ADA, ADM, AGT, ANPEP, ARNTL, CAMP, CKB, CKM, CP, CRY1,
CTGF, CTSG, DBP, GAP43, GHR, HIF1A, IER3, IGF1, IGF2, IGFBP3,
KLF9, LCN2, MAF, MAFB, PER2, PPP3CA, SERPINA3, SLC2A1,
SLPI, TF, TIMELESS, TNFRSF12A, TRPV2, VWF, WISP2
43 35 Cellular movement, behavior, nervous
system development and function
4 ADIPOQ, ADRA1D, ARC, BTK, C5orf13, Ceacam10, CSRP2, DUSP5,
FABP4, FABP5, FSTL3, GPC1, GRN, INHBA, KLF15, LMNA, LOX,
LPL, PDGFRB, PRKCB1, PRRX1, PTGES, PTGS1, RGS2, RUNX1, S100A8,
S100A9, SH3BP5, SLC2A4, STC1, THBD, TMSB10, TPMT, VCAM1, VEGF
43 35 Cellular growth and proliferation, lipid
metabolism, molecular transport
5 CA2, CBLB, CCR5, CD24, CRLF2, CSF1R, CX3CL1, CXCL10, CXCR4,
CYBA, FCGR2B, FCGR3A, HCK, ITGB2, LAT, LCP2, LYN, MATK, MME,
NCF1, PAK1, PF4, PODXL, PTK2B, PTPN6, PTPN18, PTPRE, RAC2,
SLC4A3, SRC, SYK, TEC, VAV1, VIL2, ZAP70
43 35 Immunological disease, cellular
compromise, immune and lymphatic
system development and function
6 ACP5, AIF1, BARD1, BCL2A1, BST1, C6, CCL3, CCNA2, CCNB1,
CCR1, CD14, CD40, CDC2, CORO1A, CSF1, FOXM1, HMOX1,
HPSE, ID2, IL15, IL18, ITGAM, LBP, LGALS1, MAPT, MMP9, MSLN,
PPP1R1A, PTPRO, PTTG1, SDC1, STK6, STMN1, TLR2, TNFSF11
43 35 Inﬂammatory disease, cell cycle,
tissue morphology
7 CASP1, CASP6, CDH1, CDH2, CITED2, CMA1, COL18A1, COL1A1,
COL1A2, COL5A3, DUSP1, EDNRB, EHD4, ENO2, FBLN1, GFRA1,
GJA1, GMNN, JAG1, KRT8, KRT18, KRT19, LDHA, LYZ, MFGE8, MFNG,
NEDD4, NGFB, NOV, PVR, PYCARD, RET, RIT2, SERPINF1, TNFRSF1B
43 35 Cell death, cellular movement, cancer
1195Osteoarthritis and Cartilage Vol. 15, No. 10Fig. 3. Network associated with inﬂammation and connective tissue disorders in the MIA data. Genes and gene products are nodes and
biological relationship between nodes as edges. Nodes are shown using various shapes that represent function class of the gene product.
Edges are displayed with labels that describe the nature of the relationship between the nodes. Nodes belonging to protease and chemokine
classes as well as direct and indirect interactions involving proteolysis are highlighted. All edges are supported by at least one reference from
the literature, from a textbook, or from canonical information stored in the Ingenuity Pathways Knowledge Base. The intensity of the node color
indicates the degree of up- (red) or down- (green) regulation.Discussion
Animal models represent the primary means by which
potential therapeutic agents are tested to determine the pos-
sibility of efﬁcacy in human disease. In fact, many suchagents do not translate beneﬁcial effects to humans, often
for reasons that remain elusive. In part, this is due to the
fact that most animal models are characterized with respect
to a histological phenotype and, typically, a few key molec-
ular markers. Many models mimic the phenotype, but
1196 R. A. Barve et al.: Transcriptional proﬁling and pathway analysis of MIA-induced experimental OA in ratsFig. 4. Network shown in Fig. 3 overlaid with expression values from human cartilage data.similarity to the underlying molecular components of human
disease is typically not known.
The transcriptional events occurring in chondrocytes dur-
ing OA progression are poorly understood, particularly with
regard to understanding keydifferences, if any,which charac-
terize several OA animalmodels currently in use. In this study
we have obtained an expression proﬁle from MIA stimulated
rat chondrocytes using the Agilent rat whole genome arrays
and compared this data set with the human OA expression
proﬁle. The MIA model was ﬁrst described by Kalbhen23.
This model is useful because it initiates a rapid onset of joint
damage therefore requiring shorter time and smaller doses
of compound for testing.Several groupshaveused thismodel
to study experimental OA and test compounds for the effect
on cartilage damage and pain9,12. The involvement of
MMPs in cartilage degeneration has been previously docu-
mented20,24,25 and MMP inhibitors are used to demonstrate
inhibition of cartilage damage in the MIA model26.
Other labs have reported results for MIA with concen-
trations ranging from 0.03 mg27 to 3.0 mg11,13,28. Thedifferences in published concentrations are explained by
the varying objectives of the authors ranging from under-
standing early underlying molecular changes to incapaci-
tance and pain related behaviors. In this study, a dose of
0.2 mg was chosen from an MIA titration study ranging
from 0.2 mg to 1.0 mg. At the 0.2 mg dose, consistent matrix
loss was observed, speciﬁcally, in theweight bearing regions
of the joint without total matrix loss. Higher concentrations
demonstrated up to 90% matrix loss by day 17, while at
0.2 mg the loss was approximately 35%. Given the caveat
that the human tissues were heterogeneous in nature and
the rat samples were fairly homogeneous, the 0.2 mg dose
was chosen as thematrix loss was within the observed range
of the human samples.
With reasonable conﬁdence that the transcriptional proﬁl-
ing data were accurate and that the animal data were char-
acteristic for this model, the next logical step was a direct
comparison of the human OA and rat MIA proﬁles. Upon ini-
tial review, signiﬁcant dissimilarity was observed in the
global comparison, with fewer than 4% of the differentially
1197Osteoarthritis and Cartilage Vol. 15, No. 10expressed genes from the MIA model trending in the same
direction as human OA. The data were then analyzed in
other ways that allowed for comparison of genes and path-
ways more directly associated with the disease. However,
the pathway/network and gene class analysis yielded very
similar results with little overlap between human disease
and the animal model. Speciﬁcally, within the Ingenuity
‘‘connective tissue disorder & inﬂammation’’ and MMP net-
works, few genes demonstrated similar behavior. Addition-
ally, a key observation in the gene class analysis noted
that dis-regulation of the MMP family appears to be more
pronounced in MIA than human OA.
Certain points should be noted with respect to the com-
parison of the tissue proﬁles. The human samples were har-
vested from both the tibial plateau and femoral condyle,
while the rat cartilage was harvested only from the tibial pla-
teau. Proﬁles of the human samples from both surfaces
were compared directly to each other via principal compo-
nent analysis (PCA) (data not shown here). It was deter-
mined that the variability between individuals for the same
surface was greater than the variability between the two
surfaces within an individual. Consequently, the number
of genes differing between the tibial plateau and femoral
condyle, obtained from the same patient, was small. There-
fore, samples from both surfaces were kept for the ﬁnal
analysis with the rat cartilage for completeness. Human
samples were also compared via PCA to determine if they
separated with respect to Collin’s score. The data did not
demonstrate a signiﬁcant association between the proﬁles
and degree of cartilage degradation. Additionally, it should
be noted that the human samples described as full depth
cartilage contain both the surface lesion and the underlying
tissue. The underlying tissue is phenotypically similar to
Table II
Proteases differentially expressed in cartilage from experimental
OA animals. The fold values for those in the human data set are
reported. The numbers in brackets indicate a frequency of 7 in rat
and 17 in humans. NC indicates no change at the cutoffs used.
Very few of those trend in the same direction between rat and
human data sets
Gene symbol Mean fold
change (MIA)
Mean fold change
(full depth lesion human)
MMPs
MMP12 8.13 (7) NC
MMP9 4.26 (7) NC
MMP14 3.69 (7) NC
MMP13 5.96 (7) 2.41 (2)
MMP2 2.25 (7) 2.5 (1) 2.04 (1)
MMP23 2.01 (3) 1.94 (4)
MMP3 4.27 (7) 12.43 (16)
Cathepsins
CTSC 4.77 (7) NC
CTSE 3.15 (4) NC
CTSK 3.29 (7) 1.63 (6)
CTSS 3.15 (6) NC
CTSZ 4.13 (7) 0.76 (1) 1.6 (2)
Caspases
CASP1 2.70 (3) 1.75 (16)
CASP6 2.28 (5) 1.42 (9) 1.19 (4)
Proprotein convertases
PCSK1 3.61 (6) NC
PCSK2 2.95 (4) NC
PCSK5 2.25 (4) 1.53 (5)
Serine proteases
PRSS8 1.91 (3) 2.52 (14)
CMA1 3.49 (5) NCadjacent tissue, resulting in a mixture of tissue for the pro-
ﬁling. The rats, however, were also a mixture of lesion
and non-lesion containing cartilage as no dissection was
performed. It could certainly be argued that the mixture of
tissue in human and rat was not identical and thus could
account for some discrepancies in the proﬁling.
Other limitations of the study also deserve consideration.
First, the tissue samples were carefully dissected to insure
purity, however, they were not checked for bone speciﬁc
markers. Thus it is possible some contamination may have
occurred, thought it would necessarily be a small percent-
age of the total tissue. Second, an earlier time point for the
MIA model may produce a more consistent molecular proﬁle
with human OA. Again, we believe this to be unlikely given
the high degree of similarity between the 2-week and
4-week models. Finally, changes at the level of protein
expression or post-translational modiﬁcation cannot be de-
tected directly with mRNA, thus, it is conceivable other mo-
lecular markers of OA may demonstrate greater similarity.
The primary objective of this work was the comparison of
molecular pathways and networks between the MIA model
and human OA to determine the types of targets for which
the MIA model was most suitable. For example, MMP dis-
regulation may be more aggressive in MIA but it clearly
plays a signiﬁcant role in the animal model and human dis-
ease. It is also understandable and expected as many
chronic diseases, such as OA, can take years or even de-
cades to develop in human beings. It is likely not feasible
to use animal models that develop on this time scale. It is
also reasonable to speculate that potential therapeutic tar-
gets that increase cell survivability by reducing apoptosis/
necrosis in response to MIA may translate. However, there
are numerous pathways that demonstrate little or no similar-
ity. Attempting to prosecute targets that exist in these path-
ways could lead to false positive or false negative results
and leave the researcher in a quandary if the effects do
not translate to human disease. Further proﬁling of arthritis
related in vivo and in vitro models with subsequent compar-
ison to human OA tissue is recommended to advance un-
derstanding of the relationship between these models and
human disease.
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